HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Hermann Reichenspurner Bruno Reichart Walter Klepetko Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zuckermann, A. Articles by Klepetko, W. Search for Related Content PubMed PubMed Citation Articles by Zuckermann, A. Articles by Klepetko, W. Related Collections Lung - transplantation Related Article

J Thorac Cardiovasc Surg 2003;125:891-900
© 2003 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: One-year results of a 2-center prospective randomized trial

From the Department of Cardiothoracic Surgery,^a University of Vienna, Austria, and Department of Cardiac Surgery,^b Ludwig-Maximilian University, Munich, Germany.

Received for publication Dec 28, 2001. Revisions requested March 5, 2001; revisions received Jan 3, 2002. Accepted for publication April 4, 2002. Address for reprints: Andreas O. Zuckermann, MD, Department of Cardiothoracic Surgery, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria (E-mail: 101634.174{at}compuserve.com).

Objectives: Cyclosporine (INN: ciclosporin) A or tacrolimus have been used mostly in combination with azathioprine as primary immunosuppression after lung transplantation. Benefit or risk deriving from the combination with mycophenolate mofetil are yet unknown.
Methods: In a prospective, 2-center, open randomized trial, the combination of cyclosporine A, mycophenolate mofetil, and steroids was compared with tacrolimus, mycophenolate mofetil, and steroids as primary therapy after primary lung transplantation. All patients underwent induction therapy with rabbit antithymocyte globulin for 3 days. The 2 groups were compared with regard to patient survival, freedom from acute rejection, bronchiolitis obliterans, infectious episodes, and side effects.
Results: Between September 1997 and April 1999, 74 lung transplant recipients were randomized to receive either cyclosporine A (n = 37) or tacrolimus (n = 37). Groups were comparable with regard to age, sex, transplant procedure, and cytomegalovirus match. Mean follow-up was 507 ± 258 and 508 ± 248 days, respectively. Six- and 12-month survival was similar in both groups (89% vs 84% and 82% vs 71%, respectively; P = .748 at 12 months). Two patients from the cyclosporine A group were retransplanted. Freedom from acute rejection at 6 and 12 months was comparable between groups (46% vs 51% and 35% vs 46%, respectively; P = .774 at 12 months). The mean number of treated acute rejection episodes per 100 patient-days was higher in the cyclosporine A than in the tacrolimus group, but the difference was not statistically significant (0.32 ± 0.42 vs 0.22 ± 0.30, respectively; P = .097). Four patients from the cyclosporine A group had to be switched to tacrolimus to control ongoing rejection, whereas no patient from the tacrolimus group had to be switched to cyclosporine A. There was a trend toward more infections (0.7 ± 0.36 vs 0.55 ± 0.31, P = .059) in the cyclosporine A group. New-onset diabetes mellitus was observed in the tacrolimus group only (11% vs 0%, P = .151), whereas there was a higher incidence of hypertension (60% vs 11%, P = .03) in the cyclosporine A group.
Conclusion: This 2-center, prospective randomized study showed high immunosuppressive potency of both cyclosporine A and tacrolimus in combination with mycophenolate mofetil. No significant difference in incidence of acute rejection was observed between the 2 groups. Moreover, survival and incidence of infection were similar. Incidence of drug-related adverse events were similar, yet their spectrum was different.

Related Article

Optimizing lung transplant immunosuppression: Beyond calcineurin inhibition

Michael S. Mulligan and Douglas E. Wood
J. Thorac. Cardiovasc. Surg. 2003 125: 784-786. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. Ogawa, A. L. Firth, W. Yao, L. J. Rubin, and J. X.-J. Yuan Prednisolone inhibits PDGF-induced nuclear translocation of NF-{kappa}B in human pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L648 - L657. [Abstract] [Full Text] [PDF]

				G. Ailawadi, P. W. Smith, T. Oka, H. Wang, B. D. Kozower, T. M. Daniel, I. L. Kron, and D. R. Jones Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 594 - 602. [Abstract] [Full Text] [PDF]

				N. Ide, T. Nagayasu, K. Matsumoto, T. Tagawa, K. Tanaka, T. Taguchi, Y. Sumida, and M. Nakashima Efficacy and safety of inhaled tacrolimus in rat lung transplantation J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 548 - 553. [Abstract] [Full Text] [PDF]

				J. L. Taylor and S. M. Palmer Critical Care Perspective on Immunotherapy in Lung Transplantation J Intensive Care Med, December 1, 2006; 21(6): 327 - 344. [Abstract] [PDF]

				K. A Ford Paediatric immunosuppression following solid organ transplantation Arch. Dis. Child. Ed. Pract., October 1, 2006; 91(3): ep87 - ep91. [Full Text] [PDF]

				A. S. Goldfarb-Rumyantzev, L. Smith, F. S. Shihab, B. C. Baird, A. N. Habib, S.-j. Lin, and L. L. Barenbaum Role of Maintenance Immunosuppressive Regimen in Kidney Transplant Outcome Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 563 - 574. [Abstract] [Full Text] [PDF]

				H. Furukawa, K. Oshima, T. Tung, G. Cui, H. Laks, and L. Sen Liposome-Mediated Combinatorial Cytokine Gene Therapy Induces Localized Synergistic Immunosuppression and Promotes Long-Term Survival of Cardiac Allografts J. Immunol., June 1, 2005; 174(11): 6983 - 6992. [Abstract] [Full Text] [PDF]

				R. Proctor, N. Kumar, A. Stein, D. Moles, and S. Porter Oral and Dental Aspects of Chronic Renal Failure J. Dent. Res., March 1, 2005; 84(3): 199 - 208. [Abstract] [Full Text] [PDF]

				R. Proctor, N. Kumar, A. Stein, D. Moles, and S. Porter Oral and Dental Aspects of Chronic Renal Failure Journal of Dental Research, March 1, 2005; 84(3): 199 - 208. [Abstract] [Full Text] [PDF]

				R. M. Kotloff, V. N. Ahya, and S. W. Crawford Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48. [Abstract] [Full Text] [PDF]

				K. Sarahrudi, M. Estenne, P. Corris, J. Niedermayer, C. Knoop, A. Glanville, C. Chaparro, G. Verleden, M. W. Gerbase, F. Venuta, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1126 - 1132. [Abstract] [Full Text] [PDF]

				T. M. Sievers New Antiproliferative Immunosuppressive Agents Journal of Pharmacy Practice, December 1, 2003; 16(6): 401 - 413. [Abstract] [PDF]

				M. S. Mulligan and D. E. Wood Optimizing lung transplant immunosuppression: Beyond calcineurin inhibition J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 784 - 786. [Full Text] [PDF]